Lurasidon

from Wikipedia, the free encyclopedia
Structural formula
Structure of lurasidone
General
Non-proprietary name Lurasidon
other names
  • (3a R , 4 S , 7 R , 7a S ) -2 - {(1 R , 2 R ) -2- [4- (1,2-Benzisothiazol-3-yl) -piperazin-1-ylmethyl] cyclohexylmethyl} hexahydro-1 H -4,7-methanisoindole-1,3-dione
  • SM-13496
Molecular formula C 28 H 36 N 4 O 2 S
External identifiers / databases
CAS number
  • 367514-87-2
  • 367514-88-3 (lurasidone hydrochloride )
ECHA InfoCard 100.225.187
PubChem 213046
ChemSpider 184739
DrugBank DB08815
Wikidata Q416992
Drug information
ATC code

N05 AE05

Drug class

Antipsychotic

properties
Molar mass 492.68 g · mol -1
safety instructions
Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS labeling of hazardous substances
08 - Dangerous to health 07 - Warning

Caution

H and P phrases H: 336-351
P: 202-261-308 + 313
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Lurasidone (trade name: Latuda ) is a drug that is indicated for the treatment of schizophrenia and depressive phases in the context of bipolar disorders . The substance is an atypical neuroleptic and was developed by the Japanese company Dainippon Sumitomo Pharma .

The antipsychotic effect of lurasidone is said to be based on a blockade of D 2 and 5-HT 2A receptors. In animal experiments, lurasidone was able to reverse the negative effects of the NMDA inhibitor MK-801 on the memory and learning ability of rats. The industry service Datamonitor sees lurasidone as another variant of atypical neuroleptics with limited additional therapeutic benefits.

Latuda has been approved in the US since 2010 and in the EU since March 2014 . In mid-2005, Dainippon out- licensed Sumitomo Lurasidon to the US company MSD Sharp & Dohme . However, Merck withdrew from the collaboration in 2006. Then Dainippon Sumitomo carried out the development himself again. In Germany , lurasidone was withdrawn from the market in March 2015.

See also

Web links

Individual evidence

  1. ↑ a b Registration dossier for 4,7-methano-1H-isoindole-1,3 (2H) -dione, 2 - [[(1R, 2R) -2 - [[4- (1,2-benzisothiazol-3-yl ) -1-piperazinyl] methyl] cyclohexyl] methyl] hexahydro-, (3aR, 4S, 7R, 7aS) - ( GHS section ) from the European Chemicals Agency (ECHA), accessed on July 7, 2020.
  2. ^ P. Cole, N. Serradell, E. Rosa, J. Bolos: Lurasidone hydrochloride. In: Drugs Fut. 33, 2008, pp. 316-322.
  3. ↑ T. Ishiyama, K. Tokuda, T. Ishibashi et al .: Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. In: Eur J Pharmacol . 572, 2007, pp. 160-70. PMID 17662268 .
  4. ↑ T. Enomoto, T. Ishibashi, K. Tokuda et al.: Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. In: Behav Brain Res. 186, 2008, pp. 197-207. PMID 17881065 .
  5. ↑ Datamonitor (July 2006). Pipeline Insight: Schizophrenia. ( Memento of March 22, 2014 in the Internet Archive ) (PDF file; 379 kB) Accessed November 3, 2008.
  6. ↑ US FDA: FDA approves Latuda to treat schizophrenia in adults (press release). October 28, 2010.
  7. ↑ Summary of opinion (initial authorization) . 23rd January 2014.
  8. ↑ Dainippon Sumitomo Pharma and Takeda Announce the European Marketing Authorization for Latuda® (lurasidone) , PM by Takeda March 31, 2014, accessed April 1, 2014.
  9. ↑ Dainippon Sumitomo: Review of overseas development of Lurasidone (SM-13496), an atypical antipsychotic ( Memento of March 22, 2014 in the Internet Archive ) (December 13, 2006, accessed November 1, 2008).
  10. ↑ Market withdrawals in the course of the AMNOG . December 10, 2015.